Stockpolly
Search
NVCT · NASDAQ · Biotechnology

Nuvectis Pharma (NVCT)

Develops licensed small-molecule programs across complement disease and kinase-targeted oncology.

$24.00
At close+0.94 (+4.08%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
674546678867
Research & development443334446545
232222232323
General & administrative232222232323
Operating income−6−7−4−5−4−6−6−7−8−8−6−7
000000000000
Interest income000000000−100
Other non-operating income000000000100
Income before tax−6−7−4−4−4−6−5−6−7−7−6−7
Net income from continuing operations−6−7−4−4−4−6−5−6−7−7−6−7
Net income−6−7−4−4−4−6−5−6−7−7−6−7
EPS, basic−$0.37−$0.42−$0.25−$0.26−$0.24−$0.34−$0.27−$0.30−$0.44−$0.31−$0.26−$0.30
EPS, diluted−$0.37−$0.42−$0.25−$0.26−$0.24−$0.34−$0.27−$0.30−$0.44−$0.31−$0.26−$0.30
Weighted average shares, basic161717171719202123222323
Weighted average shares, diluted161717171719202123222323
EBITDA−6−7−4−4−4−6−5−6−7−8−6−7
EBIT−6−7−4−4−4−6−5−6−7−8−6−7